top of page
Double IHC2.png

Distinguished Speakers

kaufmann.jpg

Scott Kaufmann, MD, PhD

Topic: Where We Need to be in 10 Years: A Challenge for the Decade Ahead

​

Mayo Clinic, Rochester, MN

Staff Photos(4).png

Carol Lange, PhD

Topic: History and role of Progesterone Receptor signaling in ovarian cancer models

​

University of Minnesota

2019 Speakers

MOCA’s early detection research funding and trends Kathleen Gavin Minnesota Ovarian Cancer Alliance (MOCA) Searching for needles in a haystack: Identification of early stage ovarian cancer protein biomarkers in a multiplex platform Amy Skubitz, Ph.D. University of Minnesota Tumor Associated Extracellular Vesicles: From Biomarkers to Cancer Pathogenesis Andrew Godwin, Ph.D. University of Kansas Medical Center Maximizing Natural Killer cell mediated immunotherapy in ovarian cancer via cytokine stimulation and checkpoint blockade Martin Felices, Ph.D. University of Minnesota Expression of recombinant Fc receptors by engineered lymphocytes for targeting diverse tumor antigens Bruce Walcheck, Ph.D. University of Minnesota Immune based therapies for Ovarian cancer Melissa Geller, M.D., M.S. University of Minnesota Dozens of new cancer drugs do little to improve survival Ilana Chefetz, Ph.D. Hormel Institute, University of Minnesota Microtubules stability and chemoresistance: therapeutic implications Martina Bazzaro, Ph.D. University of Minnesota Practical Components for Early Phase Discovery William Bradley, M.D. Medical College of Wisconsin

Overview on ovarian cancer metabolism Xiaonan Zhang, Ph.D. University of Solna, Sweden Oxidative Phosphorylation: a target for therapeutic strategies Ilana Chefetz, Ph.D. Hormel Institute, University of Minnesota History and role of Progesterone Receptor signaling in ovarian cancer models Carol Lange, Ph.D. University of Minnesota Progesterone receptor signaling drives DREAM-mediated quiescence and cancer cell phenotypes in models of early HGSC Laura Mauro, Ph.D. University of Minnesota Ovarian and fallopian tube communication in high grade serous ovarian cancer Joanna Burdette, Ph.D. University of Illinois Ovarian Cancer PDX Models in Preclinical and Clinical Studies John Weroha, M.D., Ph.D. Mayo Clinic, Rochester, MN On the Road to Precision Medicine in Ovarian Cancer Boris Winterhoff, M.D. University of Minnesota Probing the molecular genetics of ovarian cancer at the single cell level Tim Starr, Ph.D. University of Minnesota Where We Need to be in 10 Years: A Challenge for the Decade Ahead Scott Kaufmann, M.D., Ph.D. Mayo Clinic, Rochester, MN

bottom of page